Leukemia Research
Volume 27, Issue 3 , Pages 253-257 , March 2003

The in vitro generation of Ph1+ ALL-specific HLA-A24-restricted cytotoxic T lymphocytes using a synthetic 16 mer minor bcr–abl peptide

  • Masao Hagihara

      Affiliations

    • Department of Hematology and Rheumatology, Tokai University School of Medicine, Bohseidai, Isehara, Kanagawa 259-1193, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81-4-6393-1121; fax: +81-4-6392-4511.
    • ,
  • Takahide Tsuchiya

      Affiliations

    • Department of Hematology and Rheumatology, Tokai University School of Medicine, Bohseidai, Isehara, Kanagawa 259-1193, Japan
    • ,
  • Osamu Hyodo

      Affiliations

    • Cell Transplantation Center at the Tokai University Hospital, Bohseidai, Isehara, Kanagawa 259-1193, Japan
    • ,
  • Yoko Ueda

      Affiliations

    • Department of Hematology and Rheumatology, Tokai University School of Medicine, Bohseidai, Isehara, Kanagawa 259-1193, Japan
    • ,
  • Kei Tazume

      Affiliations

    • Department of Hematology and Rheumatology, Tokai University School of Medicine, Bohseidai, Isehara, Kanagawa 259-1193, Japan
    • ,
  • Balgansuren Gansuvd

      Affiliations

    • Department of Hematology and Rheumatology, Tokai University School of Medicine, Bohseidai, Isehara, Kanagawa 259-1193, Japan
    • ,
  • Shunichi Kato

      Affiliations

    • Department of Pediatrics, Tokai University School of Medicine, Bohseidai, Isehara, Kanagawa 259-1193, Japan
    • Genetic Engineering and Cell Transplantation Research Center at the Tokai University School of Medicine, Bohseidai, Isehara, Kanagawa 259-1193, Japan
    • ,
  • Tomomitsu Hotta

      Affiliations

    • Department of Hematology and Rheumatology, Tokai University School of Medicine, Bohseidai, Isehara, Kanagawa 259-1193, Japan

Received 3 December 2001 ,Accepted 1 June 2002.

References 

  1. Kolb JH, Mittermuller J, Clemm C, Ledderooe C, Brehm G, Heim M, et al.  Donor leukocyte infusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76:2462
  2. Collins RH, Goldstein S, Giralt S, Levine J, Porter D, Drobyski W, et al.  Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant. 2000;26:511
  3. Nakajima A, Tauchi T, Ohyashiki K. abl-specific tyrosine kinase inhibitor, STI571 in vitro, affects Ph-positive acute lymphoblastic leukemia and chronic myelogenous leukemia in blastic crisis. Leukemia. 2001;15:989
  4. Barrett A. Immune responses to chronic myeloid leukemia. Bone Marrow Transplant. 1992;9:305
  5. Pawelec G, Rehbein A, Schlotz E, de Silva P. Cellular immune responses to autologous chronic myelogenous leukemia cells in vitro. Cancer Immunol. Immunother. 1996;42:193
  6. Bocchia M, Wentworth PA, Southwood S, Sidney J, McGraw K, Scheinberg DA, et al.  Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood. 1995;85:2680
  7. Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY, Sette A, et al.  Specific human cellular immunity to bcr–abl oncogene-derived peptides. Blood. 1996;87:3587
  8. Ten Bosch GJA, Joosten AM, Kessler JH, Melief CJM, Leeksma OC. Recognition of bcr–abl positive leukemia blasts by human CD4+ T cells elicited by primary in vitro immunization with a bcr–abl breakdown peptide. Blood. 1996;88:3522
  9. Yotnda P, Firat H, Garcia-Pons F, Garcia Z, Gourru G, Vernant J-P, et al.  Cytotoxic T cell response against the chimeric p210 bcr–abl protein in patients with chronic myelogenous leukemia. J. Clin. Invest. 1998;101:2290
  10. Clark RE, Dodi IA, Hill SC, Lill JR, Aubert G, Macintyre AR, et al.  Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the bcr–abl b3a2 fusion protein. Blood. 2001;98:2887
  11. Nieda M, Nicol A, Kikuchi A, Kashiwase K, Taylor K, Suzuki K, et al.  Dendritic cells stimulate the expansion of bcr–abl specific CD8+ T cells with cytotoxic activity against leukemia cells from patients with chronic myeloid leukemia. Blood. 1998;91:977
  12. Collins RH, Shpilberg O, Drobyski WR, Porter DL, Gilralt S, Champlin R, et al.  Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Oncol. 1997;15:433
  13. Tanaka Y, Takahashi T, Nieda M, Masuda S, Kashiwase K, Ogawa S, et al.  Generation of HLA-DRB1∗1501-restricted p190 minor bcr–abl (e1a2)-specific CD4+ T lymphocytes. Br. J. Haematol. 2000;109:435
  14. Clark SS, McLaughlin J, Timmons M, Pendergast AM, Ben-Neriah Y, Dow LW, et al.  Expression of a distinctive bcr–abl oncogene in Ph1-positive acute lymphocytic leukemia. Science. 1988;239:775
  15. Chelvanayagam G. A roadmap for HLA-A, HLA-B, and HLA-C peptide binding specificities. Immunogenetics. 1996;45:15

PII: S0145-2126(02)00092-9

Leukemia Research
Volume 27, Issue 3 , Pages 253-257 , March 2003

Article Tools

* Image Usage & Resolution